Paper ID Category Paper Title Presenter City. The epidemiological features of nonalcoholic fatty liver disease- a communitybased study in Taiwan

Transcription

1 P-001 (58) 1. Epidemiology The epidemiological features of nonalcoholic fatty liver disease- a communitybased study in Taiwan Pei-Chien Tsai P-002 (60) 1. Epidemiology Finding the Missing Millions: Hepatitis screening in high-risk population groups in Pakistan. Yasir Waheed Islamabad P-003 (65) 1. Epidemiology Factors Influencing Screening of Family Members Among Index Cases of Chronic Hepatitis B Stephen Wong Manila P-004 (66) 1. Epidemiology Treatment Eligibility of Hepatitis B Patients on the Index Hepatology Visit According to APASL 2015 and EASL 2017 Criteria Stephen Wong Manila P-005 (72) 1. Epidemiology Re-appraisal Of Large-scale Community-based Hepatitis Screenings In A Township By Two Non-government Organizations Yu Ju Chen P-006 (77) 1. Epidemiology Stability Analysis and Numerical Simulation of MSIR Mathematics Model to Prevent Hepatitis B Virus Spread by Vaccination Rifaldy Fajar Yogyakarta P-007 (139) 1. Epidemiology P-008 (161) 1. Epidemiology Prevalences of HBV and HCV infection in patients undergoing chemotherapy in Taiwan Yuan-Rung Li Impact of Coffee on Liver Enzymes: Results from A Community-based Cohort Study Cheng Hung Chien P-009 (162) 1. Epidemiology The Clinical and Epidemiological Characteristics of HBV Infection in Armenia For Ghazinyan Hasmik, Mkhitharyan Aregnaz, Mkhoyan Anna, Sargsyan Sona Department of Hepatology, Nork Infection Hospital Armenia Hasmik Ghazinyan Yerevan P-010 (169) 1. Epidemiology Prevalence and Etiology of Elevated Aminotransferase Levels in Northeastern Regions of Taiwan: A Community-Based Study Cheng Hung Chien P-011 (187) 1. Epidemiology Association between metabolic syndrome and chronic virus hepatitis in Southern Taiwan: A large-scaled community study Yuan-hung Kuo P-012 (78) 2. Virology HCV RNA rebounding change in patients encountering dengue fever Po-cheng Liang P-013 (35) 4. HBV A Model to Estimate Survival in Hepatitis B Virus-Related Acute-on-Chronic Liver Failure Based on Dynamic Changes in Objective Parameters Rui Zhou Fuzhou P-014 (36) 4. HBV The influence of granulocyte colony-stimulating factor on the marrow-derived stem cells mobilization and prognosis in patients with HBV-ACLF Chun Lin Fuzhou P-015 (43) 4. HBV A Study on Clinico-Virologic Characteristics of Chronic Hepatitis B Infection in a Tertiary Care Centre Rabin Hamal Kathmandu P-016 (49) 4. HBV Efficacy and Safety of Tenofovir Alafenamide in Treatment-Experienced Chronic Hepatitis B patients P-017 (51) 4. HBV Comparisons of HBsAg changes and HBsAg loss between HBeAg-negative chronic hepatitis B patients who discontinued entecavir without retreatment and those who continued entecavir therapy Chien-Hung Chen P-018 (53) 4. HBV Hepatocellular Carcinoma among Chronic Hepatitis B patients treated with Nucleotide Analogues in China Meng Shu Shanghai P-019 (57) 4. HBV A patient with HBV reactivation with single codon substitution of S202 and N236 but without resistance mutations during Entecavir therapy Keisuke Ojiro Ichikawa P-020 (63) 4. HBV Comparison of HBV Relapse Rates between Patients Who Discontinue Entecavir and Tenofovir Disproxil Fumarate Treatment in Chronic Hepatitis B Patients beyond One Year Follow-Up Ming-Te Kuo P-021 (64) 4. HBV High percentage atypical hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogues Ching-Chung Lin P-022 (69) 4. HBV Chronic hepatitis B associates with an increased risk of B cell non-hodgkin s lymphoma and multiple myeloma Tung-hung Su P-023 (73) 4. HBV Entecavir 0.5 mg versus 1 mg in the treatment of chronic hepatitis B with severe acute exacerbation: a propensity score matching analysis Michelle Ong Chu Chiayi P-024 (79) 4. HBV The Correlations between HBV Markers in Sera and HBV ccc DNA in Various Disease States Takeshi Matsui Sapporo P-025 (83) 4. HBV The impact of hepatocellular carcinoma development on survival in patients with hepatitis B related cirrhosis receiving antiviral therapy Chih-Lin Lin P-026 (93) 4. HBV Assessment of host genomic markers associated with long-term control of hepatitis B virus in patients after interferon therapy. Hung-Chih Yang P-027 (101) 4. HBV In vivo evidences that Pre-S deletion mutants of hepatitis B virus is more likely to retain in the endoplasmic reticulum than the wild type Yuh- Jin Liang City

2 P-028 (102) 4. HBV Virological Response and Clinical Events in Patients with Chronic Hepatitis B Treated with Nucleos(t)ide Analogue Shi Chi Wen Ping-Tung P-029 (104) 4. HBV Comparison of tenofovir and entecavir on the development of acute kidney injury in cirrhotic chronic hepatitis B patient with refractory ascites Ming Chao Tsai P-030 (107) 4. HBV Tenofovir Treatment in Pregnant Women Prevents Mother-to-Infant Transmission of Hepatitis B Virus by Decreasing Neonatal Viral Exposure Kai-Chi Chang P-031 (114) 4. HBV Wisteria floribunda agglutinin-positive Mac-2-binding protein in the prediction of disease severity in chronic hepatitis B patients P-032 (119) 4. HBV Dynamic change of quantitative hepatitis B virus surface antigen level during off- treatment follow up in chronic hepatitis B patient. Poh-Poo Lim P-033 (123) 4. HBV Increase of serum Kallikrein-8 level after long-term telbivudine treatment Haw En Wang Taoyung P-034 (125) 4. HBV Beneficial effects of oligo-fucoidan in patients with chronic hepatitis B virus infection Wang-Sheng Ko P-035 (133) 4. HBV Clinical and Virological Responses of Entecavir and Tenofovir in Chronic Hepatitis B Patients with Liver Decompensation Yun-Hao Tai City P-036 (134) 4. HBV A comparative study of the effects on bone mineral density and renal toxicity in chronic hepatitis B patients with tenofovir and entecavir Tsung-Hui Hu P-037 (137) 4. HBV Impact of HBeAg seroclearance on the risk of HCC development in HBeAgpositive chronic hepatitis B patients treated with entecavir or tenofovir Jonggi Choi Seoul P-038 (138) 4. HBV Predicting risk of hepatocellular carcinoma for patients with chronic hepatitis B using serum levels of hepatitis B virus DNA splicing Mei-hung Pan P-039 (140) 4. HBV Histological steatosis is not associated with liver fibrosis severity in chronic hepatitis B patients Yi-Cheng Chen P-040 (142) 4. HBV Comparisons of the Durability of 6 and 12 months Extended HBV Prophylaxis Antiviral Therapy After Cessation Chemotherapy Po-lin Tseng P-041 (143) 4. HBV Supporting Global Efforts Toward Increasing Screening, Access, and Linkage to Care for Chronic Hepatitis B Patients Toan Vo Foster City P-042 (163) 4. HBV The incidence and predictors of retreatment in chronic hepatitis B patients after cessation of entecavir and tenofovir disoproxil fumarate TL Ma P-043 (166) 4. HBV The Eefficacy of Nucleos(t)ide Analogues Treatment for Hepatitis B e Antigenpositive Chronic Hepatitis B Patients under the Guidelines of Taiwan Bureau of National Health Insurance before 2017 Yung-Fa Chen P-044 (168) 4. HBV Reactivation of hepatitis B virus in chronic hepatitis B and C coinfected patients treated with direct-acting antiviral treatment Chien-hung Chen P-045 (170) 4. HBV Health-Related Quality of Life in Chronic Hepatitis B Carriers: A Communitybased Study in Northeastern Region of Taiwan Chang Ping Shen P-046 (174) 4. HBV A Critical Role of CD4 T Cells in IL-21-Mediated Functional Cure of Chronic HBV Yu-hua Lan P-047 (177) 4. HBV Liver fibrosis regression measured by transient elastography and APRI score among HBV patient treated with antiviral Kemal Fariz Kalista Central Jakarta P-048 (178) 4. HBV SUPPLEMENT OF SPIRULINA REDUCES QUANTITATIVE HEPATITIS B SURFACE ANTIGEN IN PATIENTS WITH CHRONIC HEPATITIS B UNDER NUCLEOS(T)IDE ANALOGUES THERAPY - AN OPEN-LABEL, RANDOMIZED CONTROLLED TRIAL Yu-An Kan P-049 (180) 4. HBV P-050 (191) 4. HBV Baseline HBV DNA level predicts the risk of clinical relapse in HBV-infected hematological malignancy patients with Rituximab-containing chemotherapy who stopped prophylactic entecavir therapy Clinical outcomes in off-nuc therapy HBeAg negative chronic hepatitis B patients whose EOT HBsAg level >200 IU/ml Wei-Yuan Chang Rachel Wen-juei Jeng P-051 (201) 4. HBV The Effect of TDF on the Hepatitis B Virus Eradication Ching-i Huang P-052 (202) 4. HBV The chance of advanced hepatic fibrosis is lower in CHB patients without fatty liver. Meng Hsuan Hsieh P-053 (205) 4. HBV P-054 (31) 6. HCV Characterization of the hepatitis B virus DNA detected in urine of chronic hepatitis B patients Patient acceptability and Efficacy of Simeprevir in addition to peginterferon and ribavirin hepatitis C genotype 1 infection Chi-Tan Hu Dexton Johns Hualien Trikakara,kochi P-055 (37) 6. HCV Daclatasvir plus asunaprevir for the treatment of HCV genotype 1b infection in Chinese patients with or without compensated cirrhosis: an integrated analysis Lai Wei Beijing

3 P-056 (38) 6. HCV P-057 (40) 6. HCV Real-World Sustained Virologic Response Rates (SVR12) withinterferon (IFN)- Free Direct Acting Antiviral (DAA) Therapy ineast Asia- Results from REAL-C (Real-World Effectiveness from the Asia Liver Consortium for Chronic Hepatitis C) Patient tolerability of Interferon and Interferon free regimen for hepatitis C infection Ming-Lung Yu Heeda Rozario Kozhikode P-058 (44) 6. HCV Real-World Experience of Direct-Acting Antiviral Agents for Chronic Hepatitis C Patients in Taiwan Chun-ming Hong City P-059 (45) 6. HCV Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan Pin-nan Cheng P-060 (46) 6. HCV The Effect of Antiviral Therapy on Serum Lipid Profiles in Chronic Hepatitis C Batbold Batsaikhan P-061 (47) 6. HCV Genotype 6 HCV infection in a high endemic area of chronic hepatitis C in southern Taiwan. Jyh-jou Chen P-062 (48) 6. HCV Elevated Serum Ferritin Level Associated with Hepatic Steatosis and Fibrosis in Hepatitis C Virus Infected Patients Batbold Batsaikhan Ulaanbaatar P-063 (50) 6. HCV P-064 (54) 6. HCV Real-world safety and efficacy of Paritaprevir/ritonavir/ombitasvir plus dasabuvir +/- ribavirin in patients with hepatitis C virus genotype 1 and compensated advanced fibrosis: a multicenter pooled analysis Augmentation of serum uric acid in chronic hepatitis C patients with curative antivirals Chih Han Liu Tyng Yuan Jang P-065 (61) 6. HCV Hepatitis C in Pakistan and analysis of HCV Polymerase gene from Pakistani Isolates Yasir Waheed Islamabad P-066 (62) 6. HCV The real world data of one year post Taiwan's national health insurance DAA reimbursement for chronic hepatitis C : an experience from primary care clinic ChienHung Lin Xilou Township, Yunlin County P-067 (68) 6. HCV P-068 (70) 6. HCV P-069 (71) 6. HCV P-070 (75) 6. HCV The real world experience of grazoprevir/elbasivr treatment for chronic hepatitis C in a single hospital of southern Taiwan Early antiviral therapy reduces the risk of lymphoma in chronic hepatitis C patients Emergence of resistant variants detected after Daclatasvir/Asunaprevir combination therapy in a compensated cirrhosis patient infected with HBV/HCV co-infection: a case report Regression of liver stiffness assessed through transient elastography in patients with chronic hepatitis C receiving direct acting antiviral agents Pin-Nan Cheng Tung-hung Su Xiaoying Zhang Wei-yu Kao Tianjin P-071 (80) 6. HCV Renal safety of directly acting antivirals treatment in chronic hepatitis C patients: real world experience Ming-Chao Tsai P-072 (81) 6. HCV Real-world Effectiveness and Safety Experience of Daclatasvir and Asunaprevir treatment in Chinese patients with hepatitis C genotype 1b infection Chengzhen Lu Tianjin City P-073 (84) 6. HCV PrOD :Taiwan- real world data from Changhua Christian Hospital Yen-Chih Lin Changhua P-074 (85) 6. HCV Association of hyperuricemia with disease severity in chronic hepatitis C patients Tyng Yuan Jang P-075 (86) 6. HCV P-076 (88) 6. HCV P-077 (99) 6. HCV Elevated Interleukin-4 Levels Predicted Advanced Fibrosis in Chronic Hepatitis C Elimination of hepatitis C virus by pegylated interferon and ribavirin after curative treatment for early hepatocellular carcinoma provided a favorable overall survival: a time-dependent analysis Ming-Ying Lu Tsung-ming Chen Efficacy and Safety of Direct-Acting Antivirals in Treatment-naïve andexperienced Patients with Chronic Hepatitis C: a real-world preliminary result Hsueh-Chou Lai P-078 (103) 6. HCV P-079 (110) 6. HCV P-080 (112) 6. HCV P-081 (121) 6. HCV The incidence of resistance-associated variants to NS5A in HCV subtypes 1a and 1b in southern Taiwan Ming Chao Tsai Real-world Experience of Efficacy and Safety Using Paritaprevir/Ritonavir, Ombitasvir and Dasabuvir for Advanced Fibrotic Genotype 1 Chronic Hepatitis C Patients Who Failed to Previous Therapy with Pegylated Interferon Plus Sih Hsien Wu Ribavirin The comparison of clinical characteristics and prognosis of HCC after antiviral therapy for HCV patients between SVR and non-svr patients Sou Fai-meng Dynamic changes of serum MHC class I chain-related A protein predict hepatocellular carcinoma in chronic hepatitis C patients after viral eradication Chung-feng Huang P-082 (122) 6. HCV P-083 (124) 6. HCV P-084 (131) 6. HCV Liver Stiffness Surveillance in Patients Treated for Chronic Hepatitis C on and off Treatment Dual oral therapy with daclatasvir plus asunaprevir for patients with HCV genotype 1b infection: A Chang Gung Medical Branches multicenter experience Treatment with Pegylated Interferon Alfa-2a plus Lower Dose Ribavirin for Hemodialysis Patients with Chronic Hepatitis C Sheng-Hung Chen Chih-Lang Lin Shi Chi Wen Ping-Tung

4 P-085 (136) 6. HCV The knowledge and will of treatment for chronic hepatitis C patients in the era of direct antiviral agents Hung-Chih Chiu City P-086 (144) 6. HCV Histological response in chronic hepatitis C patients with sustained virological response Chun-han Cheng Taitung P-087 (151) 6. HCV Efficacy and Safety of Sofosbuvir and Daclatasvir for Hepatitis C Virus Infection in Patients with β-thalassemia Amit Kumar Agrawal Indore P-088 (153) 6. HCV Association between Fibrosis Marker and Cryoglobulinemia in Patients with Chronic Hepatitis C Batbold Batsaikhan P-089 (154) 6. HCV Cryoglobulinemia is Associated with Advanced Liver Fibrosis in Chronic Hepatitis C Patients Chia-Yen Dai P-090 (155) 6. HCV Association between Renal Function and Patients with Chronic Hepatitis C Infection Gantsetseg Gantumur P-091 (167) 6. HCV P-092 (171) 6. HCV P-093 (173) 6. HCV P-094 (176) 6. HCV P-095 (181) 6. HCV P-096 (185) 6. HCV Simple score to predict risk of hepatocellular carcinoma in chronic hepatitis C patients with advanced fibrosis after pegylated interferon and ribavirin therapy Real-world experience of elbasvir/grazoprevir in Taiwan: Experience of four medical centers in Chang Gung Medical System Efficacy of Direct Acting Antivirals for Taiwanese Mixed Genotype Chronic Hepatitis C patients Unexpected rate of early tumor occurrence in patients with HCV undergoing DAA therapy in 2017 : HCC, Cholangiocarcinoma, Lung Cancer, Gastric cancer, colon cancer Daclatasvir plus asunaprevirtherapy for Taiwanese chronic hepatitis C patients with genotype 1b infection Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in southern Taiwan- a single center experience Ching-Chih Hu Yi-Chung Hsieh YU-JU WEI Chi-Yi Chen YU-JU WEI Yen Cheng Chiu Chia-yi city P-097 (188) 6. HCV Lower viral load in thalassemic hepatitis C patients Tyng Yuan Jang P-098 (189) 6. HCV Lower viral load in thalassemia splenectomy patients Tyng Yuan Jang P-099 (196) 6. HCV Is it possible to find anti-hcv-positive patients from hospital-based laboratory database? Huang-Wei Xu Chiayi P-100 (197) 6. HCV The Efficacy and Safety of Viekira pak in Chronic Hepatitis C Virus Infection: Real-World Experience of a Medical Center in Central Taiwan Shih-Ming Huang P-101 (199) 6. HCV MicroRNA expression profiles on hepatocellular carcinoma cells with different intracellular hepatitis C viral load Chia-Yen Dai P-102 (200) 6. HCV The Sofosbuvir plus daclatasvir therapy for Taiwanese patients with chronic hepatitis C virus infection Chia-Yen Dai P-103 (204) 6. HCV Recurrence of Hepatocellular Carcinoma after DAAs therapy in Taiwanese chronic HCV infection patients YU-JU WEI P-104 (206) 6. HCV P-105 (207) 6. HCV P-106 (208) 6. HCV Real-world experience with interferon-free, direct acting antiviral therapies in HCV genotype 1b-infected patients with advanced liver disease in a medically underserved island Elbasvir plus Grazoprevir for chronic genotype 1 hepatitis C virus infection: real-world experience at End of Treatment and Sustained Virological Response after treatment in a medical center Health-Related Quality of Life in Chronic Hepatitis C Carriers: A Communitybased Study in Northeastern Region of Taiwan Jung-chun Lin Wei Liang Chen Chou Tien-Shin P-107 (39) 8. HCC The Validation of GALAD Model in Diagnosis of Hepatocellular Carcinoma Qingbiao Lin Fuzhou P-108 (42) 8. HCC The Expression, Prognosis and Functional Role Of CD105 In Hepatocellular carcinoma Ming-Tsung Lin P-109 (52) 8. HCC The outcome of patients with hepatitis B virus related hepatocellular carcinoma using sorafenib in Taiwan Yuan-Hung Kuo P-110 (55) 8. HCC P-111 (56) 8. HCC Lower protein expression levels of membrane MHC class I chain-related gene A in hepatocellular carcinoma are at high risk of recurrence after surgical resection Modified Fibrosis-4 index stratifies the risk of hepatocellular carcinoma in Asian patients with chronic hepatitis B treated with entecavir Chung-Feng Huang Hung-Wei Wang P-112 (76) 8. HCC Palliative paracentesis in home hospice care for patients with hepatocellular carcinoma and liver cirrhosis Yi-Shen Wei P-113 (82) 8. HCC Transcatheter arterial chemoembolization combined with Sorafenib versus Sorafenib alone for BCLC stage C hepatocellular carcinoma: a retrospective study Hui-Fen Chen

5 P-114 (91) 8. HCC Noninvasive prognostic models for patients with hepatocellular carcinoma undergoing radiofrequency ablation Shu Yein Ho P-115 (94) 8. HCC The effect of primary prophylaxis therapy for large esophageal varices in patients with hepatocellular carcinoma Hsiao Sheng Lu P-116 (96) 8. HCC Diagnostic performance of Gadoxetic acid-enhanced MRI for hepatocellular carcinoma: a retrospective study of 65 patients Hsueh-Hao Chang P-117 (97) 8. HCC Albumin-Bilirubin grade predicts prognosis of HCC patients with repeated TACE Wei Teng P-118 (98) 8. HCC Optimal Subclassification Of BCLC Stage B Hepatocellular Carcinoma Yilin Chen P-119 (116) 8. HCC Tumor detection and identification by using Real-Time Virtual Sonography before local regional ablation Cheng-Pin Wu P-120 (118) 8. HCC Radiological Features and Outcomes of Mixed Hepatocellular and Cholangiocarcinoma in Patients undergoing Surgical Resection Chen-Ta Chi O-017 (130) 8. HCC Role of Sorafenib Combined Transcatheter Arterial Chemoembolization (TACE) in Patients with Advanced Hepatocellular Carcinoma Kebin Chang P-121 (132) 8. HCC Ten Years Experiences of Transarterial Chemoembolization in Patients with Treatment-Naïve Hepatocellular Carcinoma Xi Hsuan Lin P-122 (145) 8. HCC Treatment to Solitary Huge Hepatocellular Carcinoma (HCC) Resection is better than Transarterial Chemoembolization (TACE) Po-Chun Chen P-123 (146) 8. HCC The role of albumin-bilirubin grade in determining the long-term outcomes of patients with BCLC stage 0 HCC Chung-Yu Chang P-124 (149) 8. HCC Switching multiple-electrode radiofrequency ablation for a single hepatocellular carcinoma up to 7 cm Yi-Chung Hsieh P-125 (157) 8. HCC Comprehensive evaluation of the receptor tyrosine kinase family in human hepatocellular carcinogenesis Tony Kuo Linkou P-126 (159) 8. HCC Total Bilirubin Level Predict Survival in Hepatitis B related Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib Treatment P-127 (160) 8. HCC Viral Eradication Prolong Over Survival in Hepatitis C related Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib Treatment P-128 (165) 8. HCC An investigation for the risk factors and prognosis in HCC patients receiving transarterial chemoembolization with postembolization fever Chien-Wei Peng P-129 (172) 8. HCC Sorafenib in Combination with Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis Wei Chih Sun City P-130 (175) 8. HCC Liver resection for hepatocellular carcinoma with a zero resection margin Meng-Yu Chen P-131 (183) 8. HCC Signatures of resistance associated genes in sorafenib/ regorafenib enriched hepatocellular carcinoma cells Tsung-Hui Hu P-132 (190) 8. HCC Did AFP-L3 save ultrasonography in community screen? Chin Wei Yen Chiayi P-134 (203) 8. HCC P-135 (59) 9. Other Characteristics of Clinical Features of Hepatocellular Carcinoma in Southern Taiwan Batbold Batsaikhan Histological Course of Non-alcoholic Steatohepatitis in Taiwanese Patients: A Longitudinal Study of Sequential Liver Biopsies Taya Lin P-136 (87) 9. Other Hepatic steatosis on non-invasive liver fibrosis measurements in different Etiologies Cheng-Jen Chen Tao-Yuan P-137 (105) 9. Other Effect of Ivabradine, a Funny Current (If) Inhibitor, on Portal Hypertensive Rats Ching-Chih Chang P-138 (108) 9. Other The effect of indoles on the severity of portosystemic collaterals and mesenteric angiogenesis in cirrhotic rats Tsung-Yi Cheng P-139 (109) 9. Other An update on NAFLD and NASH in Asia Ching-sheng Hsu New P-140 (111) 9. Other The application of fatty liver index in subjects with nonalcoholic fatty liver disease: A community-based study Li-wei Chen P-141 (113) 9. Other Comparison of hepatic and splenic acoustic radiation force impulse, AST/ALT ratio, APRI and the FIB-4 index in liver resection specimens Pei-Yuan Su Changhua P-142 (115) 9. Other The Impact of Existence of Hepatitis B Virus Infection on Severe Alcoholic Liver Cirrhosis Cheng-chi Lee

6 P-143 (117) 9. Other Low Vitamin D Level Increases the Risk of Metabolic Syndrome in Subjects with Nonalcoholic Fatty Liver Disease: A Community-based Study Li-wei Chen P-144 (120) 9. Other Limited effects of antibiotic prophylaxis in patients with Child Pugh Class A/B cirrhosis and upper gastrointestinal bleeding Te Sheng Chang Chiayi P-145 (126) 9. Other Poor compensatory capability to septic shock due to adrenal insufficiency in rats with non-alcoholic fatty liver disease Shao-Jung Hsu City P-146 (127) 9. Other The impact of fatty liver disease on health related quality of life: A community based study Chang Ping Shen P-147 (128) 9. Other P-148 (129) 9. Other P-149 (147) 9. Other P-150 (148) 9. Other High serum ferritin is associated with the status of insulin resistance in subjects with non-alcoholic fatty liver disease: A community-based study Yi-Ren Chen Chronic hepatitis B exhibited higher rate of hepatocellular carcinoma occurrence than chronic hepatitis C in cirrhotic patients after effective antiviral therapies: The difference of common risk factors Kuo-chin Chang Acoustic radiation force impulse image to evaluate liver fibrosis in the patients with non-alcoholic fatty liver disease in the south Taiwan Yi-hung Lin The long-term recurrence rate of Helicobacter pylori infection after successful eradication in Taiwan Hsu Ben Lin P-151 (150) 9. Other Identification of novel oncogenic hepatitis B virus X gene mutations in Entecavirtreated patients Shu-Ting Lin P-152 (152) 9. Other The difference of clinical characteristics between lean and obese patients with nonalcoholic fatty liver disease Yi-Chung Hsieh P-153 (156) 9. Other Effect of Dioscin on the Synthesis of Endothelin-1 in Hepatic Stellate Cells Che-chang Chan P-154 (158) 9. Other Relationship between serum total bilirubin levels and mortality in uremia patients undergoing long-term hemodialysis: A nationwide cohort study Hui Hsien Su P-155 (186) 9. Other Comparison of Seven Prognostic Models For Spontaneous Bacterial Peritonitis Chien-Hao Huang P-156 (209) 4. HBV A Case Series Study of Chronic Hepatitis C and B Dual Infection Patients Treated by Oral Anti-HCV Agents (Daas): Effectiveness Evaluation in Anti-HCV Therapy and Clinical Influence in Chronic Hepatitis B Chi-chieh Yang Changhua